albumin-bound paclitaxel / Generic mfg. - LARVOL DELTA

Emerging nanoparticle-based therapies for pancreatic cancer: Current clinical landscape. (PubMed, Adv Drug Deliv Rev) - "Clinically approved NPs such as nab-Paclitaxel and liposomal Irinotecan have demonstrated improved pharmacokinetics and therapeutic benefits in PDAC...The integration of artificial intelligence and machine learning could further optimize NP design and patient stratification. Overall, nanotechnology represents a crucial frontier of research for developing more effective and personalized pancreatic cancer treatments."

Journal • Review • Immunology • Oncology • Pancreatic Cancer • Solid Tumor

Treatment-Related Toxicities and Functional Outcomes in Vulnerable Older Adults with Metastatic Pancreatic Cancer: Analysis from ECOG-ACRIN EA2186 (SIOG 2025) - "Patients were randomized to Arm A: Gemcitabine/Nab-Paclitaxel or Arm B: 5-FU/Leucovorin/Liposomal Irinotecan... Both regimens had distinct toxicity profiles relevant to older adults. These findings may inform treatment selection and supportive care strategies for vulnerable older adults with mPDAC."

Clinical • Metastases • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Exploring Stereotactic Radiotherapy in Elderly Pancreatic Cancer Patients: A Safe and Effective Approach? (SIOG 2025) - "Chemotherapy was administered in 85.6% of patients, mainly Gem-Abraxane (75.6%)... SBRT is a well-tolerated and effective option for elderly PC patients. When combined with chemotherapy, it may be a valid non-surgical strategy or facilitate surgery in selected cases. Our results suggest that outcomes in elderly patients are not inferior to those observed in younger populations."

Clinical • Oncology • Pancreatic Cancer • Solid Tumor

Treatment-Related Toxicities and Functional Outcomes in Vulnerable Older Adults with Metastatic Pancreatic Cancer: Analysis from ECOG-ACRIN EA2186 (SIOG 2025) - "Patients were randomized to Arm A: Gemcitabine/Nab-Paclitaxel or Arm B: 5-FU/Leucovorin/Liposomal Irinotecan... Both regimens had distinct toxicity profiles relevant to older adults. These findings may inform treatment selection and supportive care strategies for vulnerable older adults with mPDAC."

Clinical • Metastases • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Treatment-Related Toxicities and Functional Outcomes in Vulnerable Older Adults with Metastatic Pancreatic Cancer: Analysis from ECOG-ACRIN EA2186 (SIOG 2025) - "Patients were randomized to Arm A: Gemcitabine/Nab-Paclitaxel or Arm B: 5-FU/Leucovorin/Liposomal Irinotecan... Both regimens had distinct toxicity profiles relevant to older adults. These findings may inform treatment selection and supportive care strategies for vulnerable older adults with mPDAC."

Clinical • Metastases • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Exploring Stereotactic Radiotherapy in Elderly Pancreatic Cancer Patients: A Safe and Effective Approach? (SIOG 2025) - "Chemotherapy was administered in 85.6% of patients, mainly Gem-Abraxane (75.6%)... SBRT is a well-tolerated and effective option for elderly PC patients. When combined with chemotherapy, it may be a valid non-surgical strategy or facilitate surgery in selected cases. Our results suggest that outcomes in elderly patients are not inferior to those observed in younger populations."

Clinical • Oncology • Pancreatic Cancer • Solid Tumor

Exploring Stereotactic Radiotherapy in Elderly Pancreatic Cancer Patients: A Safe and Effective Approach? (SIOG 2025) - "Chemotherapy was administered in 85.6% of patients, mainly Gem-Abraxane (75.6%)... SBRT is a well-tolerated and effective option for elderly PC patients. When combined with chemotherapy, it may be a valid non-surgical strategy or facilitate surgery in selected cases. Our results suggest that outcomes in elderly patients are not inferior to those observed in younger populations."

Clinical • Oncology • Pancreatic Cancer • Solid Tumor

Treatment-Related Toxicities and Functional Outcomes in Vulnerable Older Adults with Metastatic Pancreatic Cancer: Analysis from ECOG-ACRIN EA2186 (SIOG 2025) - "Patients were randomized to Arm A: Gemcitabine/Nab-Paclitaxel or Arm B: 5-FU/Leucovorin/Liposomal Irinotecan... Both regimens had distinct toxicity profiles relevant to older adults. These findings may inform treatment selection and supportive care strategies for vulnerable older adults with mPDAC."

Clinical • Metastases • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Treatment-Related Toxicities and Functional Outcomes in Vulnerable Older Adults with Metastatic Pancreatic Cancer: Analysis from ECOG-ACRIN EA2186 (SIOG 2025) - "Patients were randomized to Arm A: Gemcitabine/Nab-Paclitaxel or Arm B: 5-FU/Leucovorin/Liposomal Irinotecan... Both regimens had distinct toxicity profiles relevant to older adults. These findings may inform treatment selection and supportive care strategies for vulnerable older adults with mPDAC."

Clinical • Metastases • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Exploring Stereotactic Radiotherapy in Elderly Pancreatic Cancer Patients: A Safe and Effective Approach? (SIOG 2025) - "Chemotherapy was administered in 85.6% of patients, mainly Gem-Abraxane (75.6%)... SBRT is a well-tolerated and effective option for elderly PC patients. When combined with chemotherapy, it may be a valid non-surgical strategy or facilitate surgery in selected cases. Our results suggest that outcomes in elderly patients are not inferior to those observed in younger populations."

Clinical • Oncology • Pancreatic Cancer • Solid Tumor

Efficacy of systemic therapy in HER2-low breast cancer with CNS metastases: a "real-world" experience (SABCS 2025) - "Systemic therapies for the CNS disease included cytotoxic chemotherapy in seven patients (44%), trastuzumab deruxtecan (T-DXd) in four (25%), abemaciclib in two (13%), other CDK4/6 inhibitors in two (13%), and sacituzumab govitecan in one (6%). Commonly utilized chemotherapy included taxanes (paclitaxel or nab-paclitaxel) in 4 of 7 patients... This "real-world" experience highlights modest intracranial activity of systemic therapy in HER2-low breast cancer with CNS metastases. Although response rates were lower than in HER2-positive counterparts, HER2 2+ tumors and patients treated with T-DXd showed encouraging outcomes. These findings support the need for prospective studies focusing on HER2-low CNS disease and suggest T-DXd as a promising therapeutic option, even in the absence of concurrent local treatment."

Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Herthena-breast04: a phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician's choice in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) unresectable locally advanced or metastatic breast cancer (SABCS 2025) - "Participants in Arm 1 will receive HER3-DXd 5.6 mg/kg IV on day 1 Q3W, and participants in Arm 2 will receive TPC consisting of 1 of the following options: 1) paclitaxel 80 mg/m2 IV on days 1, 8, 15, and 22 Q4W; 2) paclitaxel 90 mg/m2 IV on days 1, 8, and 15 Q4W; 3) nab-paclitaxel 100 mg/m2 IV on days 1, 8, and 15 Q4W; 4) capecitabine 1000 mg/m2 orally twice daily on days 1 to 14 Q3W; 5) liposomal doxorubicin 50 mg/m2 IV on day 1 Q4W; or 6) trastuzumab deruxtecan 5.4 mg/kg IV on day 1 Q3W. Imaging assessments occur Q6W from randomization through week 60 and Q12W thereafter. Enrollment is planned to begin in Q3 2025 across North America, Latin America, Europe, and Asia Pacific."

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ERBB3 • HER-2

First Preclinical Evaluation of Inavolisib-Based Combinatorial Strategies in PIK3CA-Mutant Breast Cancer Brain Metastasis Models (SABCS 2025) - "For TNBC models, combinations included PD-1 antibody and albumin-bound paclitaxel. For HER2-positive models, Inavolisib was combined with Trastuzumab + Pertuzumab, T-DXd (Trastuzumab deruxtecan), or Tucatinib...This study provides the first preclinical evidence of Inavolisib-based combination strategies in PIK3CA-mutant breast cancer brain metastases, using both novel intracranial animal models and PDX systems. Our results suggest that: Inavolisib combined with PD-1 antibody is a promising regimen for TNBC with brain metastases; Inavolisib + T-DXd or Trastuzumab + Pertuzumab shows potent activity in HER2-positive BCBM. These findings highlight the potential of PI3K-targeted combinatorial strategies for overcoming the BBB challenge in breast cancer brain metastases and provide a strong rationale for clinical translation."

IO biomarker • Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PIK3CA

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=792 | Recruiting | Sponsor: Hoffmann-La Roche | N=580 ➔ 792 | Trial completion date: May 2028 ➔ Sep 2030 | Trial primary completion date: May 2028 ➔ Sep 2030

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PIK3CA

INTerpath-13: A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

GOBLET: A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab (clinicaltrials.gov) - P1/2 | N=122 | Recruiting | Sponsor: Oncolytics Biotech

Biomarker • New P1/2 trial • Anal Carcinoma • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • PD-L1

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study). (PubMed, Int J Cancer) - P | "With mFOLFIRINOX as first-line treatment, mOS was 11.3 months (95% CI, 8.6-13.5 months), with gemcitabine/nab-paclitaxel 10.5 months (95% CI, 8.3-12.9 months). Predictive variables for proceeding from first to second-line therapy were reasons for ending first-line treatment (patient's wish, toxicity, and progressive disease) and age. In summary, we were able to show in detail patient flows and QoL data throughout all therapy lines, which will help to further understand the major clinical checkpoints of the disease."

HEOR • Journal • Oncology • Pancreatic Cancer • Solid Tumor

ETNA: Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer (ANZCTR) - P3 | N=632 | Completed | Sponsor: Fondazione Michelangelo | Active, not recruiting ➔ Completed

Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • HER-2 • PGR

Disseminated Superficial Actinic Porokeratosis in a Woman With Metastatic Pancreatic Cancer During Chemotherapy With Capecitabine and Nab-Paclitaxel. (PubMed, Australas J Dermatol) - "We report a case of disseminated superficial actinic porokeratosis (DSAP) in a 73-year-old woman with metastatic pancreatic cancer undergoing chemotherapy with capecitabine and nab-paclitaxel. This case suggests a possible association between DSAP and the use of these chemotherapeutic agents, emphasising the need for awareness of atypical dermatologic reactions in such patients."

Journal • Oncology • Pancreatic Cancer • Solid Tumor

RASolute 302: Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov) - P3 | N=501 | Active, not recruiting | Sponsor: Revolution Medicines, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Ivonescimab for EGFR-mutant lung adenosquamous carcinoma after multiline therapy: A case report. (PubMed, Front Oncol) - "Despite initial responses to first-line firmonertinib-based combination therapy, progression-free survival (PFS) 13 months, the patient developed sequential resistance to subsequent regimens, including liver/brain metastases and treatment-related toxicities. After fourth-line therapy failure and severe intolerance to albumin-bound paclitaxel and bevacizumab, two cycles of ivonescimab-a first-in-class programmed cell death protein receptor-1 (PD-1)/vascular endothelial growth factor-A (VEGF-A) bispecific antibody-induced significant regression of pulmonary target lesions (PR), sustained over six cycles with minimal toxicity...While the rapid PR and favorable safety profile are promising, longer follow-up is required to assess durability and survival benefits. These findings underscore the need for further investigation of bispecific antibodies in precision oncology paradigms for multi-refractory EGFR-driven NSCLC."

IO biomarker • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • PD-1 • PD-L1 • TP53

NOTABLE-309: Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - P2 | N=156 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P2 trial • Oncology • Pancreatic Cancer • Solid Tumor

TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC): early safety and efficacy results in participants (pts) from Asia (ESMO Asia 2025) - P3 | "We report early safety and efficacy data within a subgroup of pts from Asia. Pts receive D 1500 mg (first infusion: 60 min; subsequent infusions: 30 min) with an investigator-selected G-based chemotherapy (D + G alone or in combination with oxaliplatin [O], carboplatin [C], cisplatin [cis], tegafur-gimeracil-oteracil [S-1], cis + S-1, or cis + nab-paclitaxel [P]). In pts from Asia, the safety profiles of all study tx were manageable. Safety results for pts from Asia were comparable to the global TOURMALINE population and TOPAZ-1 study. Interim ORR is promising."

Clinical • Combination therapy • Metastases • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Neoadjuvant chemo-immunotherapy with camrelizumab plus chemotherapy in resectable or potentially resectable locally advanced head and neck squamous cell carcinoma: an open-label, single-arm, phase II trial (ESMO Asia 2025) - P2 | "Enrolled patients received camrelizumab (200 mg, iv, q3w) in combination with albumin-paclitaxel (260 mg/m2, iv, q3w) and platinum (cisplatin 75 mg/m2 or carboplatin AUC 5, iv, q3w) for 2 cycles. Neoadjuvant chemotherapy plus camrelizumab for locally advanced HNSCC showed potential efficacy and an acceptable safety profile. This encouraging result promotes us to continue this phase Ⅱ study."

Clinical • Metastases • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A patient with metastatic upper tract urothelial carcinoma with EGFR exon 20 insertion and MTAP loss responding to amivantamab and pemetrexed-based chemotherapy (ESMO Asia 2025) - P2 | "Gemcitabine and carboplatin were started but lung metastasis worsened. He was switched to pembrolizumab without significant response. He was then given sacituzumab govitecan, with initial improvement but progressed later. He later had enfortumab vedotin and rechallenged carboplatin with nab-paclitaxel, and had further enlargement of lung metastasis...Our case offers insights into a patient with refractory urothelial carcinoma with EGFR exon 20 insertion and MTAP loss, having early and durable response to amivantimab and pemetrexed-carboplatin despite the failure of multiple prior therapies. This supports further investigation of broad molecular profiling and biomarker-guided trials in urothelial carcinoma to understand tissue-specific effects of genetic alterations."

Clinical • EGFR exon 20 • IO biomarker • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer • CDKN2A • CDKN2B • EGFR • FGFR • HER-2 • MTAP • PD-L1 • PIK3CA • TP53